the frequency of transfusions but did not control the thrombocytopenia, and splenectomy has been performed. No radiological changes in the bone have been observed after six months' treatment but there has been little growth over this period.
Comment
These 2 patients illustrate the main features of the severe form of osteopetrosis and the major problems of management, which are control of the bony and hiematological abnormalities. A low calcium diet has had encouraging results in one patient but it is still too early to assess long-term prognosis. Acknowledgments: I am grateful to Dr J R Harper and the late Dr A V C Lloyd for referring the patients, and to Professor C E Dent for kindly arranging the 59Fe uptake study. History: Presented in July 1968 aged 9 months with several grand mal convulsions: the first had occurred after a febrile episode one week after triple vaccine immunization. Investigation revealed no cause for the convulsions. The serum calcium (October 1969), after fourteen months' treatment with phenobarbitone, was 7.5 mg/100 ml, but this was not pursued at the time. Over the next 31 years he was treated with phenobarbitone 30-90 mg daily for fifteen months, primidone 500 mg daily for twenty-five months, and phenytoin 90-120 mg daily for twenty months. His fits were poorly controlled and it became clear that he was retarded; his speech was delayed and his behaviour restless and sometimes aggressive. In March 1971 his parents noticed bowing of the legs and X-rays showed florid rickets. September 1971: X-rays showed healing of rickets. Serum calcium 9.1, serum phosphate 4.0 mg/l00 ml. Serum alkaline phosphatase 83 K-A units per 100 ml. Progress: Since vitamin D was started the dose of anticonvulsants has been lowered, omitting phenytoin altogether. The frequency of his fits has decreased. Comment Osteomalacia and rickets have been described in patients taking anticonvulsants (Kruse 1968 (quoted by Reynolds 1970), Dent et al. 1970) . Two surveys of patients in institutions , Hunter et al. 1971 ) showed reduced serum calcium and raised alkaline phosphatase levels in 20-25 % of those on anticonvulsants and there was a correlation between total amount taken or duration of treatment and degree of abnormality.
It has been suggested that anticonvulsant drugs, particularly phenytoin, phenobarbitone and primidone, induce hepatic microsomal enzymes which are responsible for degrading and conjugating various substances, including bilirubin, corticosteroids and vitamin D. In the presence of these drugs, the conversion of vitamin D3, the normally ingested form, to 25-hydroxycholecalciferol, the metabolically active form, is believed to be accelerated. The further hydroxylation of this substance to less active derivatives and their conjugation with glucuronic acid is also thought to proceed more rapidly, resulting in a raised dietary requirement of the vitamin to maintain normal plasma levels. Such a mechanism would clearly unmask borderline vitamin D deficiency to which poor diet, lack of sunlight and skin pigmentation may contribute, especially in institutionalized epileptics.
Conclusions
Biochemical evidence of osteomalacia and rickets should be sought in patients on anticonvulsants for more than two to three years, particularly those at risk from poor diet and lack of sunlight, e.g. coloured immigrants. It is possible that a poor diet was partially responsible in this child as he was difficult to manage at home and both parents were Indian, although they claimed that he ate a normal western diet. Neither his parents nor his elder brother had symptoms suggesting dietary deficiency. If anticonvulsants can lower serum calcium in the way described, the liability to fits may increase unless vitamin D supplements are given.
